New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
about
Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine groupIn vitro anti-Mycobacterium avium activities of quinolones: predicted active structures and mechanistic considerationsAnti-Mycobacterium avium activity of quinolones: in vitro activitiesN-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studiesA DNA gyrase-binding site at the center of the bacteriophage Mu genome is required for efficient replicative transpositionMycoplasma pneumoniae DNA gyrase genes.The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action.The evolving role of chemical synthesis in antibacterial drug discovery.DNA gyrase: structure and function.The role of fluorine in medicinal chemistry.Photoactive assemblies of organic compounds and biomolecules: drug-protein supramolecular systems.Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II.Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.Purification of Citrobacter freundii DNA gyrase and inhibition by quinolonesIn vitro cleavable-complex assay to monitor antimicrobial potency of quinolones.Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics.Effect of DNA gyrase inhibitors pefloxacin, five other quinolones, novobiocin, and clorobiocin on Escherichia coli topoisomerase I.Fluorine in medicinal chemistry.Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli.Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples.Anti-Mycobacterium avium activity of quinolones: structure-activity relationship studiesDrug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential.In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency.3,4-dimethoxyphenyl bis-benzimidazole, a novel DNA topoisomerase inhibitor that preferentially targets Escherichia coli topoisomerase IReversible suppression by nalidixic acid of anchorage-independent growth of mouse cells transformed by 3-methylcholanthrene or an activated c-Ha-ras geneEffects of quinolones on nucleoid segregation in Escherichia coliRelationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones.Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agentsOptimization of a novel potent and selective bacterial DNA helicase inhibitor scaffold from a high throughput screening hit.A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Synthesis and In-vitro Antibacterial Activities of Acetylanthracene and Acetylphenanthrene Derivatives of Some Fluoroquinolones.In vitro assays used to measure the activity of topoisomerases.Introduction of fluorine and fluorine-containing functional groups.The DNA cleavage reaction of DNA gyrase. Comparison of stable ternary complexes formed with enoxacin and CcdB protein.Recent advances in fluorination techniques and their anticipated impact on drug metabolism and toxicity.Structure-activity relationships of the fluoroquinolones.Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.Mode of action, and in vitro and in vivo activities of the fluoroquinolones.High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
P2860
Q24671373-BEBC62D3-268A-4249-B30A-365931DC77A1Q28369137-7C5DD3FF-89E8-451B-97A1-F740A665F656Q28378348-7C4AB74C-69E2-454C-B543-66F417F3FD20Q28379303-D0354867-B135-4D30-BBD9-E926B0CE41A2Q33887701-C976243D-E6B4-4B09-B67D-07757B8CF6DBQ33950253-8F599934-5B44-4B19-AE15-E5084ECD9B35Q34092838-870ED957-E90B-49C5-97B6-3C0B4D3627E8Q34427652-88495079-946B-4839-9B3B-75698659504BQ34507230-F7E165F2-67C5-41DC-A72D-EBFD888BFC57Q34717922-A2445D56-99A7-4235-ADEE-A624CBB1C62CQ35123150-D47EF7BC-FA2C-4F3B-9DBF-0CB3D4C85BAEQ35277460-E6DC18AD-79A2-4269-9ABA-178E81E55033Q35284580-1C285803-67E9-4955-A9B4-EE3B6A918779Q35289324-B245C910-C34C-44BA-8094-24DD68683354Q35314754-64D06488-1CF0-4F7F-94CC-AF435AFD5FB3Q35315975-2DD6EF39-3615-4DFC-8C93-A7B9928F527AQ35558361-50076A5A-F201-4EC3-BEFE-5390E434423DQ35562756-AF83844C-F403-4CBA-8E4F-BB69232F8D29Q35762548-1101B867-94FD-4BD3-825B-2333DFED972AQ35810503-2930359E-DA68-4082-A993-5DB5F6D41A73Q35816625-6F250E8C-E779-43C4-9149-26061351266EQ35818942-086D3185-04E1-437A-81B2-4454CA385E6DQ35897465-6CCEFF2D-38A9-48B4-81BB-5AFA59F4C4E3Q35904010-FE531EB9-619E-4BE1-9814-82A1DBF70239Q36389231-F3C63FC5-5FF3-438E-9C3F-F1178569E96DQ36467821-F1F603A9-9A00-49A5-98C9-6977EC9F0F5AQ36757605-B1328448-31AB-48F0-91D1-B8A64EE86A12Q36758128-FC3BB8A3-20DA-43D6-9347-24F5F25AD746Q36857113-AF48F5EE-CF6E-4FE0-BAA0-D7D2F79A07C0Q36950824-9692969A-5889-4464-A347-EA026B99098FQ37204002-7DBD50EA-A781-4162-B86A-CE8B6DE84247Q37310785-21DBE42F-0386-441E-A20C-2590DF03EE79Q37876263-5890FD52-3292-4A2E-B5D0-4EAD7EAE002AQ38123135-CE27DF06-604F-4793-8E8E-0B46B2CADCCFQ38342333-33FE7C29-BA13-4BA0-A08E-B7B3364DE5A6Q38366495-72F57E15-5432-41DC-A703-A3888F98C077Q38629697-79BCD6F0-C43B-417A-AAAA-CAD8A78484EDQ39214819-39F81878-9577-4EDD-AF9A-060ED88126C4Q39637667-D4630DF0-996F-48F3-BE50-832A54DF33EEQ39665406-DAB122FE-1288-4FB3-A003-300824B8B31D
P2860
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
New structure-activity relatio ...... ication of a DNA gyrase assay.
@en
type
label
New structure-activity relatio ...... ication of a DNA gyrase assay.
@en
prefLabel
New structure-activity relatio ...... ication of a DNA gyrase assay.
@en
P2093
P356
P1476
New structure-activity relatio ...... ication of a DNA gyrase assay.
@en
P2093
Domagala JM
Heifetz CL
Sanchez JP
P304
P356
10.1021/JM00153A015
P407
P577
1986-03-01T00:00:00Z